Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.
暂无分享,去创建一个
S. Ménard | N. Cascinelli | G. Bonadonna | S. Pilotti | L. Gianni | E. Biganzoli | P. Boracchi | E. Marubini | P. Valagussa | P. Casalini | G. Tomasic | L. Gianni | M. Colnaghi
[1] Philip Smith,et al. Effect of c‐erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil , 1999, International journal of cancer.
[2] M. Fernö,et al. Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications , 1999, The Journal of pathology.
[3] B Fisher,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.
[4] D A Berry,et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.
[5] L. Norton,et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. , 1997, Oncology.
[6] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Skoog,et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. , 1995, European Journal of Cancer.
[8] G. Bonadonna,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.
[9] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[10] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[11] G. Laub,et al. A stratified product limit estimator for the follow-up study in cardio-thoracic surgery , 1993 .
[12] Johannes Gerdes,et al. Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.
[13] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[16] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[17] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.